Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study
Objective: We evaluated the efficacy, safety, and drug survival rate of tocilizumab in the elderly patients with rheumatoid arthritis (RA). Methods: This study was conducted in 108 RA patients who started tocilizumab between 2008 and 2018. The patients were divided into a young group (<65 years)...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-09-01
|
| Series: | European Journal of Inflammation |
| Online Access: | https://doi.org/10.1177/20587392211045790 |
| _version_ | 1818651753514532864 |
|---|---|
| author | Yoshinobu Nakao Yu Funakubo Asanuma Takuma Tsuzuki Wada Mayumi Matsuda Hiroaki Yazawa Yoshihiro Yoshida Akira Todoriki Ayumi Shintani Toshihide Mimura |
| author_facet | Yoshinobu Nakao Yu Funakubo Asanuma Takuma Tsuzuki Wada Mayumi Matsuda Hiroaki Yazawa Yoshihiro Yoshida Akira Todoriki Ayumi Shintani Toshihide Mimura |
| author_sort | Yoshinobu Nakao |
| collection | DOAJ |
| description | Objective: We evaluated the efficacy, safety, and drug survival rate of tocilizumab in the elderly patients with rheumatoid arthritis (RA). Methods: This study was conducted in 108 RA patients who started tocilizumab between 2008 and 2018. The patients were divided into a young group (<65 years) and an elderly group (≥65 years). The efficacy, safety, and drug survival rate of tocilizumab were compared between the two groups. Results: At baseline, there were no significant differences between the elderly ( n = 45) and the young group ( n = 63) in RA duration, percentage of biologic-naïve, and RA disease activity. Health Assessment Questionnaire-Disability Index (HAQ-DI) was higher, renal function was worse, and frequency of using methotrexate was lower in the elderly group. Tocilizumab demonstrated similar efficacy in the elderly and the young group with Clinical Disease Activity Index and HAQ-DI. Compared with baseline, the frequency of steroid use was lower at one year after initiation of tocilizumab in both groups. There was no significant difference between the groups in the drug survival rate of tocilizumab for three years. Discontinuation rates of TCZ due to toxic adverse events were similar between the two groups. Conclusions: The efficacy, steroid-sparing effect, and safety of tocilizumab therapy, as well as the drug survival rate for three years, were not inferior in elderly RA compared to young RA patients. |
| first_indexed | 2024-12-17T02:11:07Z |
| format | Article |
| id | doaj.art-40bf5bde4d984b6b9bd4dfa2440ba935 |
| institution | Directory Open Access Journal |
| issn | 2058-7392 |
| language | English |
| last_indexed | 2024-12-17T02:11:07Z |
| publishDate | 2021-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | European Journal of Inflammation |
| spelling | doaj.art-40bf5bde4d984b6b9bd4dfa2440ba9352022-12-21T22:07:32ZengSAGE PublishingEuropean Journal of Inflammation2058-73922021-09-011910.1177/20587392211045790Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational studyYoshinobu NakaoYu Funakubo AsanumaTakuma Tsuzuki WadaMayumi MatsudaHiroaki YazawaYoshihiro YoshidaAkira TodorikiAyumi ShintaniToshihide MimuraObjective: We evaluated the efficacy, safety, and drug survival rate of tocilizumab in the elderly patients with rheumatoid arthritis (RA). Methods: This study was conducted in 108 RA patients who started tocilizumab between 2008 and 2018. The patients were divided into a young group (<65 years) and an elderly group (≥65 years). The efficacy, safety, and drug survival rate of tocilizumab were compared between the two groups. Results: At baseline, there were no significant differences between the elderly ( n = 45) and the young group ( n = 63) in RA duration, percentage of biologic-naïve, and RA disease activity. Health Assessment Questionnaire-Disability Index (HAQ-DI) was higher, renal function was worse, and frequency of using methotrexate was lower in the elderly group. Tocilizumab demonstrated similar efficacy in the elderly and the young group with Clinical Disease Activity Index and HAQ-DI. Compared with baseline, the frequency of steroid use was lower at one year after initiation of tocilizumab in both groups. There was no significant difference between the groups in the drug survival rate of tocilizumab for three years. Discontinuation rates of TCZ due to toxic adverse events were similar between the two groups. Conclusions: The efficacy, steroid-sparing effect, and safety of tocilizumab therapy, as well as the drug survival rate for three years, were not inferior in elderly RA compared to young RA patients.https://doi.org/10.1177/20587392211045790 |
| spellingShingle | Yoshinobu Nakao Yu Funakubo Asanuma Takuma Tsuzuki Wada Mayumi Matsuda Hiroaki Yazawa Yoshihiro Yoshida Akira Todoriki Ayumi Shintani Toshihide Mimura Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study European Journal of Inflammation |
| title | Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study |
| title_full | Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study |
| title_fullStr | Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study |
| title_full_unstemmed | Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study |
| title_short | Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study |
| title_sort | efficacy safety and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis a real world observational study |
| url | https://doi.org/10.1177/20587392211045790 |
| work_keys_str_mv | AT yoshinobunakao efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT yufunakuboasanuma efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT takumatsuzukiwada efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT mayumimatsuda efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT hiroakiyazawa efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT yoshihiroyoshida efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT akiratodoriki efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT ayumishintani efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT toshihidemimura efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy |